Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/publications/10321-survival-after-neoadjuvant-chemotherapy-with-or-without-bevacizumab-or-everolimus-for-her2-negative-primary-breast-cancer-gbg-44-geparquinto/authors?page=5